(E)-3-(2-(5-nitrofuran-2-yl)ethenyl)-1H-pyrazole | 1055927-92-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: (E)-3-(2-(5-nitrofuran-2-yl)ethenyl)-1H-pyrazole
• 英文别名: (E)-3-(2-(5-nitrofuran-2-yl)vinyl)-1H-pyrazole；5-[(E)-2-(5-nitrofuran-2-yl)ethenyl]-1H-pyrazole
• CAS: 1055927-92-8
• 化学式: C₉H₇N₃O₃
• 分子量: 205.173
• InChiKey: YKUVDPWPDNKMPQ-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY
  申请人：Angion Biomedica Corp.

  公开号：US20180009793A1

  公开（公告）日：2018-01-11

  The present invention provides compositions and formulations of compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein p, R 1 , R 2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease.

  本发明提供具有公式（I）及其药学上可接受的衍生物的组合物和配方，其中p，R1，R2和B如本文中一般和在类和子类中所述，并提供其制药组合物以及使用它们治疗HGF/SF或其活性或其激动剂或拮抗剂在治疗中有治疗用途的任何损伤，疾病或疾病的方法。此外，还提供了治疗这些疾病或在损伤，疾病或疾病发病后的时间开始治疗的方法。
• Small molecule modulators of hepatocyte growth factor (scatter factor) activity
  申请人：Zembower E. David

  公开号：US20080015243A1

  公开（公告）日：2008-01-17

  The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 , R 2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role.

  本发明提供具有公式（I）的化合物及其药学上可接受的衍生物，其中R1、R2和B如本文中一般和在各类和亚类中所描述的，并且还提供了其制药组合物，以及使用它们治疗HGF/SF或其活性或其激动剂或拮抗剂在治疗中具有治疗用途的多种情况或疾病的方法。
• Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
  申请人：ANGION BIOMEDICA CORP.

  公开号：US10899750B2

  公开（公告）日：2021-01-26

  The present invention provides compositions and formulations of compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein p, R1, R2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease.

  本发明提供了具有式(I)：的化合物及其药学上可接受的衍生物的组合物和制剂，其中p、R1、R2和B如本文一般和类及亚类中所述，此外还提供了其药物组合物，以及使用其治疗HGF/SF或其活性或其激动剂或拮抗剂具有治疗作用的多种损伤、病症或疾病中任何一种的方法。 此外，还提供了在损伤、病症或疾病发生后开始治疗此类疾病的方法。
• Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
  申请人：Angion Biomedica Corp.

  公开号：EP2292227B1

  公开（公告）日：2016-08-24
• METHODS OF USE OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY
  申请人：Angion Biomedica Corp.

  公开号：EP2624830A2

  公开（公告）日：2013-08-14